Mar 9, 2026 04:09PM Jones Trading Reiterates Buy Rating on iBio, Inc. (IBIO): "we expect the stock to move in sympathy with readouts from WVE and ARWR"

Mar 9, 2026 07:02AM iBio reports fat reduction in primate study of obesity drug candidate

Mar 2, 2026 04:16PM Jones Trading Starts iBio, Inc. (IBIO) at Buy

Feb 11, 2026 12:29AM iBio, Inc. (IBIO) reported Q2 EPS

Jan 30, 2026 04:13PM iBio, Inc. (IBIO) files for 11.06M share offering by selling stockholders

Oct 30, 2025 07:00AM iBio reports extended half-life data for obesity drug candidate

Oct 20, 2025 04:07PM Oppenheimer Starts iBio, Inc. (IBIO) at Outperform, PT $5

Sep 5, 2025 01:01PM Brookline Capital Markets Reiterates Buy Rating on iBio, Inc. (IBIO)

Aug 27, 2025 04:37PM iBio, Inc. (IBIO) PT Lowered to $1.60 at Brookline Capital Markets

Jun 25, 2025 07:58AM Chardan Comments on iBio, Inc. (IBIO)

Jun 23, 2025 04:15PM iBio, Inc. (IBIO) Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates

Jun 16, 2025 07:03AM iBio (IBIO) Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 13, 2025 09:04AM iBio, Inc. (IBIO) Files for 11.25M Share Offering by Selling Stockholders

Apr 29, 2025 01:44PM iBio, Inc. (IBIO) Raises $6.2M Through Warrant Inducement Transaction

Apr 22, 2025 08:02AM iBio, Inc. (IBIO) Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025 07:00AM iBio, Inc. (IBIO) Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth

Jan 7, 2025 07:01AM iBio, Inc. (IBIO) Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

Aug 12, 2024 04:31PM iBio, Inc. (IBIO) Appoints Kristi Sarno as VP of Business Development

Jul 25, 2024 05:14PM iBio, Inc. (IBIO) Files $150M Mixed Shelf

Jul 22, 2024 08:30AM Brookline Capital Markets Starts iBio, Inc. (IBIO) at Buy